Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Kunyu Shi, Guan Wang, Junping Pei, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Qingfang Li, Yan Tie, Aqu Alu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 130
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
Shenduo Li, Guilherme Sacchi de Camargo Correia, Jing Wang, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2899-2899
Open Access | Times Cited: 39
Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor receptor tyrosinase inhibitors
Rohit Pal, Ghanshyam Teli, Gurubasavaraja Swamy Purawarga Matada, et al.
Journal of Molecular Structure (2023) Vol. 1291, pp. 136021-136021
Closed Access | Times Cited: 36
Engineered M13 phage as a novel therapeutic bionanomaterial for clinical applications: From tissue regeneration to cancer therapy
Cheng Chang, Wennan Guo, Xinbo Yu, et al.
Materials Today Bio (2023) Vol. 20, pp. 100612-100612
Open Access | Times Cited: 35
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
Satyam Singh, Sushabhan Sadhukhan, Avinash Sonawane
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 188967-188967
Closed Access | Times Cited: 35
Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor
Yuesheng Zhang
Pharmacological Reviews (2023) Vol. 75, Iss. 6, pp. 1218-1232
Open Access | Times Cited: 33
Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox
Dirk H. Siepe, Lora K. Picton, K. Christopher García
ACS Synthetic Biology (2023) Vol. 12, Iss. 4, pp. 1081-1093
Open Access | Times Cited: 27
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer
Fortunato Ciardiello, Fred R. Hirsch, Robert Pirker, et al.
Cancer Treatment Reviews (2023) Vol. 122, pp. 102664-102664
Open Access | Times Cited: 25
Resveratrol, Epigallocatechin Gallate and Curcumin for Cancer Therapy: Challenges from Their Pro-Apoptotic Properties
Adele Chimento, Maria D’Amico, Arianna De Luca, et al.
Life (2023) Vol. 13, Iss. 2, pp. 261-261
Open Access | Times Cited: 23
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 10
Targeting HER3 to overcome EGFR TKI resistance in NSCLC
Qiuqiang Chen, Gang Jia, Xilin Zhang, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 9
From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
Siqi Wang, Fuchu He, Chunyan Tian, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 1, pp. 100-100
Open Access | Times Cited: 9
Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies
Wei‐Fang Zuo, Qiwen Pang, Xinyu Zhu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 9
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
Huajun Chen, Hai‐Yan Tu, Yanping Hu, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Photodynamic therapy for glioblastoma: A light at the end of the tunnel
Mariana Miretti, María Antonella González Graglia, Agustín I. Suárez, et al.
Journal of Photochemistry and Photobiology (2023) Vol. 13, pp. 100161-100161
Open Access | Times Cited: 19
Single-cell gene set enrichment analysis and transfer learning for functional annotation of scRNA-seq data
Melania Franchini, Simona Pellecchia, Gaetano Viscido, et al.
NAR Genomics and Bioinformatics (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 18
In silico and in vitro evaluation of novel carbothioamide-based and heterocyclic derivatives of 4-(tert-butyl)-3-methoxybenzoic acid as EGFR tyrosine kinase allosteric site inhibitors
Imad M. Malik AL-Rubay, Ammar A. Razzak Mahmood, Lubna H. Tahtamouni, et al.
Results in Chemistry (2024) Vol. 7, pp. 101329-101329
Open Access | Times Cited: 6
Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer
Simona Pellecchia, Melania Franchini, Gaetano Viscido, et al.
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 6
A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma
Qian Liang, Miaomiao Gong, Jing-Hua Zou, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100957-100957
Open Access | Times Cited: 13
Design, synthesis, anticancer activity and docking studies of novel quinazoline-based thiazole derivatives as EGFR kinase inhibitors
M.S. Raghu, Hassan A. Swarup, T. R. Shamala, et al.
Heliyon (2023) Vol. 9, Iss. 9, pp. e20300-e20300
Open Access | Times Cited: 13
Cutting-Edge Therapies for Lung Cancer
Anita Silas La’ah, Shih-Hwa Chiou
(2024)
Open Access | Times Cited: 5
Emerging paradigms and recent progress in targeting ErbB in cancers
Nicolas Stoup, Maxime Liberelle, Nicolas Lebègue, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 552-576
Open Access | Times Cited: 5
Accelerated drug-resistant variant discovery with an enhanced, scalable mutagenic base editor platform
Kristel M. Dorighi, Anqi Zhu, Jean‐Philippe Fortin, et al.
Cell Reports (2024) Vol. 43, Iss. 6, pp. 114313-114313
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top